Arrowhead Pharmaceuticals Inc. (ARWR) Prices 4M Share Offering at $58/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Pre-Open 12/03: (BOLD) (VRAY) (ALDX) Higher (CBL) (CARA) (CLF) Lower (more...)
December 3, 2019 9:16 AM ESTToday's Pre-Open Movers
Audentes Therapeutics, Inc. (NASDAQ: BOLD) 105% HIGHER; Astellas Pharma Inc. and Audentes Therapeutics, Inc. (NASDAQ: BOLD) today announced that they have entered into a definitive agreement for Astellas to acquire Audentes at a price of US$60.00 per share in cash, representing a total equity value of approximately US$3 billion.
CBL Properties (NYSE: CBL) 33% LOWER; announced that it is suspending all future dividends on its common stock, 7.375% Series D Cumulative Redeemable... More
After-Hours Movers 12/02: (BOLD) (VRAY) (ILPT) Higher; (CBL) (AGTC) (KOD) Lower (more...)
December 2, 2019 6:08 PM ESTToday's After-Hours Movers
Audentes Therapeutics, Inc. (NASDAQ: BOLD) 109% HIGHER; Astellas Pharma Inc. and Audentes Therapeutics, Inc. (NASDAQ: BOLD) today announced that they have entered into a definitive agreement for Astellas to acquire Audentes at a price of US$60.00 per share in cash, representing a total equity value of approximately US$3 billion.
CBL Properties (NYSE: CBL) 33% LOWER; announced that it is suspending all future dividends on its common stock, 7.375% Series D Cumulative Redeemable Preferred... More
Arrowhead Pharmaceuticals Inc. (ARWR) Announces Proposed 4M Share Common Offering
December 2, 2019 4:06 PM ESTArrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced its intention to offer and sell 4,000,000 shares of its common stock in an underwritten offering pursuant to its existing automatic shelf registration statement. All of the shares in the proposed offering are to be sold by Arrowhead.... More
Arrowhead Pharmaceuticals (ARWR) Trades at Low, Down 8.5%
December 2, 2019 10:57 AM ESTArrowhead Pharmaceuticals Corp (NASDAQ: ARWR) Trades at Low, Down 8.5%
... More